<<Lotsa companies working with GPCRs. Fewer with orphan receptors, perhaps. My guess is TLRK has a major lead there, but they aren't as focused on CNS disorders.>>
tuck,
You have made a jump that I have observed on other threads. "Orphan receptors" is too broad a term.
Yes, TLRK has an "orphan receptor" program, but it targets nuclear orphans (intracellular receptors, nuclear hormone receptors, whatever you wish to call them). They don't target CNS because nuclear receptors are not (thought of as) CNS targets (although ER-beta signalling is postulated to lead to CNS effects, and my guess is some nuclear orphans will probably be correlated with CNS effects). TLRK has NO GPCR program of which I am aware. Their biggest competitors in this arena are X-Ceptor Therapeutics and a group at Glaxo in RTP.
GPCRs are classical CNS targets, and there are orphan GPCRs as well. Certainly Synaptic is involved here, and Arena's reason for being is identifying orphan GPCR function. I would guess that NBIX is looking at GPCR orphans, but can't point you at a link to back up that claim. As to a leader in the orphan GPCR field, I'll have to yield the floor to others -- haven't studied this as much as I would have liked to.
Perhaps this discussion could be moved to the TLRK or an Arena thread -- the bullets seem to be flying hot and heavy here. My first visit is liable to be my last.
(Go Rick!! Go Miljenko!!) |
